RHHBY Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -- compared to Roche Holding AG's net margin of 32.59%. Roche Holding AG's return on equity of 23.8% beat Eli Lilly and's return on equity of 80.24%.

Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 9.3%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 22.98%. Given that Eli Lilly and has higher upside potential than Roche Holding AG, analysts believe Eli Lilly and is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Roche Holding AG has a quarterly dividend of $1.36 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Roche Holding AG's net income of -- is lower than Eli Lilly and's net income of $4.4B. Notably, Roche Holding AG's price-to-earnings ratio is 29.51x while Eli Lilly and's PE ratio is 70.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.88x versus 16.49x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -- compared to Roche Holding AG's net margin of 32.95%. Roche Holding AG's return on equity of 23.8% beat Novo Nordisk AS's return on equity of 86.85%.

Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 9.3%. On the other hand Novo Nordisk AS has an analysts' consensus of $106.57 which suggests that it could grow by 57.11%. Given that Novo Nordisk AS has higher upside potential than Roche Holding AG, analysts believe Novo Nordisk AS is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.420, suggesting its less volatile than the S&P 500 by 58.038%.

Roche Holding AG has a quarterly dividend of $1.36 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.06% to investors and pays a quarterly dividend of $0.52 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Novo Nordisk AS quarterly revenues of $12.2B. Roche Holding AG's net income of -- is lower than Novo Nordisk AS's net income of $4B. Notably, Roche Holding AG's price-to-earnings ratio is 29.51x while Novo Nordisk AS's PE ratio is 21.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.88x versus 7.44x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -- compared to Roche Holding AG's net margin of 20.79%. Roche Holding AG's return on equity of 23.8% beat Novartis AG's return on equity of 27.64%.

Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 9.3%. On the other hand Novartis AG has an analysts' consensus of $109.37 which suggests that it could fall by -1.82%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.528, suggesting its less volatile than the S&P 500 by 47.174%.

Roche Holding AG has a quarterly dividend of $1.36 per share corresponding to a yield of 0%. Novartis AG offers a yield of 3.47% to investors and pays a quarterly dividend of $3.87 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.6B. Roche Holding AG's net income of -- is lower than Novartis AG's net income of $2.8B. Notably, Roche Holding AG's price-to-earnings ratio is 29.51x while Novartis AG's PE ratio is 18.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.88x versus 4.38x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Roche Holding AG's net margin of 2.31%. Roche Holding AG's return on equity of 23.8% beat Pfizer's return on equity of 8.91%.

Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 9.3%. On the other hand Pfizer has an analysts' consensus of $31.26 which suggests that it could grow by 24.98%. Given that Pfizer has higher upside potential than Roche Holding AG, analysts believe Pfizer is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Roche Holding AG has a quarterly dividend of $1.36 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.76% to investors and pays a quarterly dividend of $0.43 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Roche Holding AG quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.8B. Roche Holding AG's net income of -- is lower than Pfizer's net income of $410M. Notably, Roche Holding AG's price-to-earnings ratio is 29.51x while Pfizer's PE ratio is 17.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.88x versus 2.24x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.